TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22677568
Drug: Polyethylene glycol
Normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyethylene glycol 3350 with electrolytes (PEG+E) 0.5 g/kg daily
Study: 17964516
Drug: Thalidomide (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thalidomide (100 mg every 6 hours for 5 doses)
Study: 12196491
Drug: Complete liquid
Normalized name: Ensure Complete Liquid
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Complete liquid nutrition supplement containing energy, vitamins, and minerals, including enhanced levels of antioxidants
Study: 12196491
Drug: Complete liquid
Normalized name: Ensure Complete Liquid
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Complete liquid nutrition supplement
Study: 12196491
Drug: Complete liquid
Normalized name: Ensure Complete Liquid
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Complete liquid nutrition supplement and Noncaloric placebo drink
Study: 7778530
Drug: Delapril 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delapril 7.5 mg twice daily, increased to 15 mg twice daily after 2 weeks
Study: 7778530
Drug: Enalapril 2.5
Normalized name: enalapril 2.5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 2.5 mg twice daily, increased to 5 mg twice daily after 2 weeks
Study: 6938020
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose Stilboestrol
Study: 31722536
Drug: Autonomic regulation
Normalized name: AUTONOMIC MEDICATIONS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autonomic regulation therapy plus guideline-directed medical therapy
Study: 10367415
Drug: Radical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radical treatment of localized disease
Study: 8006249
Drug: Angina-guided plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angina-guided plus ambulatory ECG ischemia-guided medical therapy
Study: 1234491
Drug: Cyclizine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclizine (50 mg)
Study: 1234491
Drug: Perphenazine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perphenazine (5 mg)
Study: 1234491
Drug: Perphenazine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perphenazine (2.5 mg)
Study: 23581458
Drug: Standard preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard preparation of V. cinerea for 3 months
Study: 23581458
Drug: Standard preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard preparation of V. cinerea
Study: 21812735
Drug: Desvenlafaxine 200
Normalized name: Desvenlafaxine
DrugBank: Desvenlafaxine (DB06700)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desvenlafaxine 200 to 400 mg/d
Study: 19804822
Drug: Co-therapy with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-therapy with topiramate (TPR)
Study: 16434675
Drug: Glatiramer acetate
Normalized name: Glatiramer Acetate
DrugBank: Glatiramer (DB05259)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glatiramer acetate therapy
Study: 9185645
Drug: Arbutamine infusion
Normalized name: ARBUTAMINE
DrugBank: Arbutamine (DB01102)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Arbutamine infusion with technetium-99m sestamibi
Study: 9185645
Drug: Arbutamine infusion
Normalized name: ARBUTAMINE
DrugBank: Arbutamine (DB01102)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Arbutamine infusion with echocardiography
Study: 3534315
Drug: Fluoxymesterone for
Normalized name: Fluoxymesterone
DrugBank: Fluoxymesterone (DB01185)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluoxymesterone for 3 days before and on the day of chemotherapy
Study: 3534315
Drug: Cyclic intravenous
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclic intravenous chemotherapy with aminoglutethimide and hydrocortisone
Study: 22015818
Drug: teriparatide 20
Normalized name: TERIPARATIDE 200UNT/VIL INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: teriparatide 20 μg/d
Study: 22015818
Drug: alendronate 10
Normalized name: ALENDRONATE 10MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: alendronate 10 mg/d
Study: 20549236
Drug: Artesunate (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artesunate (standard dosage schedule)
Study: 12858617
Drug: 24-week theory-based
Normalized name: Sel-24 free base
DrugBank: SEL-24 (DB18082)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24-week theory-based physical activity program (treatment group, n = 29)
Study: 27006452
Drug: Self‐guided therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self‐guided therapy
Study: 24977347
Drug: Agomelatine 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Agomelatine 400 mg
Study: 22162481
Drug: 0.2 mg/kg/wk
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg/kg/wk LB03002 for 12 months, followed by 0.5 mg/kg/wk for another 24 months (n=13)
Study: 22162481
Drug: 0.5 mg/kg/wk
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg/wk LB03002 for 36 months (n=13)
Study: 22162481
Drug: 0.7 mg/kg/wk
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.7 mg/kg/wk LB03002 for 12 months, followed by 0.5 mg/kg/wk for another 24 months (n=13)
Study: 22162481
Drug: Daily GH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily GH 0.03 mg/kg/d for 24 months, switched to 0.5 mg/kg/wk LB03002 for 12 months (n=12)
Study: 20412107
Drug: Oral D-penicillamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral D-penicillamine (DPA) at 100 mg/kg/dose every 8 hours for 3 days, followed by 50 mg/kg/day for 11 days
Study: 20412107
Drug: Oral D-penicillamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral D-penicillamine (DPA)
Study: 9063959
Drug: Pentoxifylline (PTX)
Normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentoxifylline (PTX) 400 mg three times daily for 1 week before surgery
Study: 1715297
Drug: cream base
Normalized name: Cream Base
Approvals — FDA: no, EMA: no, PMDA: no
Description: cream base only
Study: 30477961
Drug: Linezolid 600
Normalized name: linezolid 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linezolid 600 mg/day for 2 weeks
Study: 30477961
Drug: Linezolid 600
Normalized name: linezolid 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linezolid 600 mg/day for 4 weeks
Study: 17888856
Drug: CBT+NRT (nicotine
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBT+NRT (nicotine replacement therapy)
Study: 10737427
Drug: SQV‐SGC 1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: SQV‐SGC 1200 mg, NFV 750 mg, SQV‐SGC 800 mg plus NFV 750 mg, all with two NRTIs, and SQV‐SGC 800 mg plus NFV 750 mg alone, all three times daily for 48 weeks
Study: 10737427
Drug: Quadruple therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadruple therapy (SQV‐SGC and NFV)
Study: 10737427
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy with either single protease inhibitor
Study: 8933488
Drug: 14% CHO
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14% CHO solution (HCHO)
Study: 8933488
Drug: 7% CHO
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7% CHO solution (NCHO)
Study: 8933488
Drug: 4.2% CHO
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4.2% CHO solution (LCHO)
Study: 1425883
Drug: Bezafibrate 400
Normalized name: bezafibrate 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bezafibrate 400 mg/day (slow release formulation)
Study: 29461392
Drug: 500‐mL colloid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500‐mL colloid preload followed by 500‐mL crystalloid coload
Study: 29461392
Drug: 1000‐mL crystalloid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000‐mL crystalloid coload
Study: 27893820
Drug: Placebo 500
Normalized name: placebo 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 500 mg once daily for three days
Study: 12209673
Drug: Pemetrexed/gemcitabine combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed/gemcitabine combination
Study: 10617249
Drug: Continuous 1
Normalized name: Uniphyllin Continus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous 1 mg E2
Study: 10617249
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg E2/30 microg NGM
Study: 10617249
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg E2/90 microg NGM
Study: 10617249
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg E2/180 microg NGM
Study: 7856897
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (10 mg.kg‐1 followed by 1 mg.kg‐1.h‐1)
Study: 7856897
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (doses < 10 mg.kg‐1)
Study: 7856897
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (all doses)
Study: 2023868
Drug: Ultrasound treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound treatment (3.0 MHz, 1.0 W/cm2 for 5 min)
Study: 2023868
Drug: Placebo control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo control (massage with gels without ultrasound for 5 min)
Study: 31355692
Drug: Usual occupational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual occupational therapy (Control)
Study: 25545380
Drug: ZOL (zoledronic
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZOL (zoledronic acid) 5 mg annually for 9 years (Z9)
Study: 25545380
Drug: Placebo (Z6P3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (Z6P3) after 6 years of ZOL treatment
Study: 20061311
Drug: Combined intervention
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined intervention (CC + PST)
Study: 16270636
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin (certoparin 3000 anti Xa IU) subcutaneously once-daily
Study: 16270636
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (5000 IU) subcutaneously three-times daily
Study: 16270636
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin (certoparin)
Study: 7601298
Drug: Thymomodulin treatment
Normalized name: thymomodulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymomodulin treatment
Study: 394268
Drug: lidamidine hydrochloride
Normalized name: lidamidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: lidamidine hydrochloride (10 mg)
Study: 394268
Drug: lidamidine hydrochloride
Normalized name: lidamidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: lidamidine hydrochloride (18 mg)
Study: 31320504
Drug: Music medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music medicine (noise-canceling headphone-delivered)
Study: 31320504
Drug: Midazolam (1-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (1-2 mg intravenous)
Study: 23289819
Drug: Rosuvastatin 20
Normalized name: rosuvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 20 mg for 10 days
Study: 16766412
Drug: 24-hour nicotine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24-hour nicotine patch
Study: 16766412
Drug: 16-hour nicotine
Normalized name: nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 16-hour nicotine patch
Study: 15534490
Drug: Subcutaneous CPG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous CPG 7909 injection
Study: 15534490
Drug: Subcutaneous CPG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous CPG 7909 injection (second dose)
Study: 15534490
Drug: Intravenous CPG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous CPG 7909 injection
Study: 11251475
Drug: Bicarbonate solution
Normalized name: Potassium Bicarbonate
DrugBank: Potassium bicarbonate (DB11098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bicarbonate solution
Study: 11251475
Drug: Lactate solution
Normalized name: lactate Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactate solution
Study: 8296180
Drug: Regular deep
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular deep relaxation training (15 min sessions, daily for 6 months)
Study: 29551350
Drug: Eberconazole 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eberconazole 1% otic solution
Study: 18793575
Drug: Avosentan 50
Normalized name: Bosentan
DrugBank: Bosentan (DB00559)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Avosentan 50 mg after a high-fat, high-calorie breakfast
Study: 18793575
Drug: Avosentan 50
Normalized name: Bosentan
DrugBank: Bosentan (DB00559)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Avosentan 50 mg administered in the fasted state
Study: 2352762
Drug: Transcutaneous electrical
Normalized name: Transcutaneous Electrical Nerve Stimulators (TENS Units) MISCELL EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcutaneous electrical nerve stimulation (TENS) with naloxone (50 mg)
Study: 103114
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of haloperidol and low dose piribedil
Study: 28392165
Drug: sorafenib or
Normalized name: sorafenib Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: sorafenib or sunitinib (targeted therapy)
Study: 19541299
Drug: GnRH analogue
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH analogue treatment for 2 months before surgery
Study: 19541299
Drug: Direct surgery
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct surgery without preoperative medical treatment
Study: 12190134
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg ketorolac + 15 mg codeine phosphate
Study: 12190134
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg ketorolac + codeine
Study: 12190134
Drug: Codeine in
Normalized name: codeine Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Codeine in combination
Study: 8882400
Drug: Multivitamin supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multivitamin supplementation (0.8 mg of folic acid daily)
Study: 8882400
Drug: Trace element
Normalized name: trace elements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trace element supplement (placebo-like)
Study: 1519784
Drug: Transdermal fentanyl
Normalized name: fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Transdermal fentanyl 25 micrograms.h‐1
Study: 6831829
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 500 mg acetaminophen and 65 mg caffeine
Study: 6831829
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg acetaminophen alone
Study: 31418532
Drug: Brochure about
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brochure about venous disease and compression therapy (case group)
Study: 22502624
Drug: 1.0% copaiba
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0% copaiba essential oil preparation
Study: 10348287
Drug: Intensive doxorubicin-containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive doxorubicin-containing chemotherapy and whole-lung irradiation
Study: 10348287
Drug: Less aggressive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Less aggressive treatment with 2 or 3 drugs without whole-lung irradiation
Study: 7586616
Drug: Naloxone 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone 20 mg
Study: 7586616
Drug: Ovine corticotrophin‐releasing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ovine corticotrophin‐releasing hormone (oCRH) 1 microgram/kg
Study: 7586616
Drug: Insulin 0.15U/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin 0.15U/kg
Study: 1849413
Drug: AVE‐5 regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: AVE‐5 regimen (etoposide 60 mg/m2 IV on day 1 and 120 mg/m2 orally on days 2-5)
Study: 1849413
Drug: AVE‐1 regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: AVE‐1 regimen (etoposide 300 mg/m2 IV on day 1)
Study: 6418074
Drug: Chemo-endocrine therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemo-endocrine therapy (TAM+) with Mitomycin-C plus Tegafur and Tamoxifen 20 mg/day
Study: 6418074
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (TAM-)
Study: 6418074
Drug: Chemo-endocrine therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemo-endocrine therapy (TAM+) in curatively resected cases
Study: 6418074
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (TAM-) in curatively resected cases
Study: 30693573
Drug: AL-335 800
Normalized name: Al
DrugBank: Aluminium (DB01370)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AL-335 800 mg, odalasvir 25 mg, and simeprevir 75 mg once daily for 6 weeks
Study: 30693573
Drug: AL-335 800
Normalized name: Al
DrugBank: Aluminium (DB01370)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AL-335 800 mg, odalasvir 25 mg, and simeprevir 75 mg once daily for 8 weeks
Study: 27267785
Drug: Buprenorphine/naloxone rapidly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine/naloxone rapidly dissolving tablets
Study: 31336393
Drug: Î±‐tocopherol acetate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Î±‐tocopherol acetate (150mg/L)
Study: 31336393
Drug: Pinus ponderosa
Normalized name: PINUS PONDEROSA POLLEN
DrugBank: Pinus ponderosa pollen (DB10746)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pinus ponderosa leaves (150mg/L)
Study: 31336393
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Pinus ponderosa leaves (70mg) and Î±‐tocopherol acetate (70mg)
Study: 27986684
Drug: RG-TFV rectal
Normalized name: DNA, D((2'-O-(2-METHOXYETHYL))M5RC-SP-(2'-O-(2-METHOXYETHYL))RA-(2'-O-(2-METHOXYETHYL))RG-SP-(2'-O-(2-METHOXYETHYL))RG-(2'-O-(2-METHOXYETHYL))RA-SP-T-SP-A-SP-M5C-SP-A-SP-T-SP-T-SP-T-SP-M5C-SP-T-SP-A-SP-(2'-O-(2-METHOXYETHYL))M5RC-(2'-O-(2-METHOXYETHYL))R
Approvals — FDA: no, EMA: no, PMDA: no
Description: RG-TFV rectal gel daily
Study: 27986684
Drug: RG-TFV rectal
Normalized name: DNA, D((2'-O-(2-METHOXYETHYL))M5RC-SP-(2'-O-(2-METHOXYETHYL))RA-(2'-O-(2-METHOXYETHYL))RG-SP-(2'-O-(2-METHOXYETHYL))RG-(2'-O-(2-METHOXYETHYL))RA-SP-T-SP-A-SP-M5C-SP-A-SP-T-SP-T-SP-T-SP-M5C-SP-T-SP-A-SP-(2'-O-(2-METHOXYETHYL))M5RC-(2'-O-(2-METHOXYETHYL))R
Approvals — FDA: no, EMA: no, PMDA: no
Description: RG-TFV rectal gel before and after receptive anal intercourse (RAI)
Study: 27986684
Drug: Daily gel
Normalized name: Phisoderm Clear Confidence Daily Gel Face Wash
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily gel regimen
Study: 22654431
Drug: Ranitidine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (300 mg twice daily)
Study: 19626811
Drug: Intrathecal 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal 1.25 mg hyperbaric bupivacaine plus cerebrospinal fluid 0.75 ml
Study: 19626811
Drug: Propofol 1‐1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 1‐1.5 mg/kg IV bolus dose and 6‐10 mg/kg/hr infusion
Study: 17366527
Drug: Once-daily ceftriaxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily ceftriaxone plus amikacin (C + A)
Study: 17366527
Drug: Imipenem monotherapy
Normalized name: Imipenem
DrugBank: Imipenem (DB01598)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Imipenem monotherapy (control)
Study: 9442542
Drug: Scavenging at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scavenging at 45 L/min evacuation rate
Study: 3067809
Drug: Fencamfamine 25
Normalized name: Fencamfamin
DrugBank: Fencamfamin (DB01463)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fencamfamine 25 mg
Study: 3067809
Drug: Fencamfamine 50
Normalized name: Fencamfamin
DrugBank: Fencamfamin (DB01463)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fencamfamine 50 mg
Study: 24351501
Drug: Antidepressants (adequate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressants (adequate dose for at least 6 weeks)
Study: 18443395
Drug: Aqueous nasal
Normalized name: Pen-Aqueous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqueous nasal spray 100 microg twice daily
Study: 18443395
Drug: Nasal drop
Normalized name: Nasal Drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal drop preparation 400 microg once daily
Study: 18443395
Drug: Nasal drop
Normalized name: Nasal Drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal drop preparation 400 microg twice daily
Study: 10913928
Drug: Cyclical hPTH(1-34)
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclical hPTH(1-34) therapy (50 microg/day for 28 days in 3-month cycles)
Study: 1417010
Drug: Tegafur suppository
Normalized name: tegafur
DrugBank: Tegafur (DB09256)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Tegafur suppository preoperatively + tegafur oral preparation postoperatively
Study: 1417010
Drug: Tegafur suppository
Normalized name: tegafur
DrugBank: Tegafur (DB09256)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Tegafur suppository preoperatively + UFT oral preparation postoperatively
Study: 1417010
Drug: Tegafur oral
Normalized name: tegafur Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tegafur oral preparation postoperatively
Study: 1417010
Drug: Preoperative tegafur
Normalized name: tegafur
DrugBank: Tegafur (DB09256)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Preoperative tegafur administration
Study: 1417010
Drug: Dukes B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dukes B patients with preoperative tegafur administration
Study: 3893024
Drug: 1% Butoconazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% Butoconazole nitrate (BN) vaginal cream
Study: 3893024
Drug: 2% Butoconazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% Butoconazole nitrate (BN) vaginal cream
Study: 3893024
Drug: 2% Miconazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% Miconazole nitrate (MN) vaginal cream
Study: 31272493
Drug: Inhaled methoxyflurane
Normalized name: methoxyflurane Nasal Inhalant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled methoxyflurane (maximum dose of 2 × 3 ml)
Study: 31272493
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline placebo (maximum dose 2 × 5 ml)
Study: 26329381
Drug: Citalopram (CIT)
DrugBank: Citalopram (DB00215)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Citalopram (CIT) 20 mg/day for 35 days with anodal tDCS
Study: 26329381
Drug: Citalopram (CIT)
DrugBank: Citalopram (DB00215)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Citalopram (CIT) 20 mg/day for 35 days with cathodal tDCS